Zura Bio Ltd
ZURANasdaq
$5.45
↑ +3.8%Jul 17 close · end-of-day
Price
1Y↑ +322.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$611.6M
Enterprise Value
$386.0M
P/E
—
P/S
—
P/B
2.8
EV/EBITDA
—
PEG
—
FCF Yield
-11.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$75.4M
Free Cash Flow (TTM)
-$72.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-34.8%
ROIC
—
Debt / Equity
—
Net Cash
$225.6M
Return 1Y
+178.1%
Company profile
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
- CEO
- Someit Sidhu
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- California
- Website
- zurabio.com
Earnings
ZURA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.22↑ +15.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$27.2M | -$62.6M | -$55.2M | -$75.2M |
| Net income | -$25.7M | -$60.4M | -$52.4M | -$68.7M |
| Diluted EPS | -$141.97 | -$2.09 | -$0.60 | -$1.06 |
| Operating cash flow | -$1.2M | -$15.1M | -$28.1M | -$64.8M |
| Free cash flow | — | — | -$28.2M | -$64.9M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$11.8M | -$19.3M | -$15.7M | -$19.3M | -$18.1M | -$19.5M | -$18.4M | -$25.5M |
| Net income | -$10.3M | -$20.7M | -$13.6M | -$17.4M | -$16.0M | -$18.0M | -$17.2M | -$24.2M |
| Diluted EPS | -$0.17 | -$0.26 | -$0.15 | -$0.19 | -$0.17 | -$0.21 | -$0.49 | -$0.22 |
| Operating cash flow | -$6.6M | -$5.7M | -$10.8M | -$11.1M | -$16.0M | -$15.4M | -$22.3M | -$18.9M |
| Free cash flow | -$6.6M | -$5.7M | -$10.9M | -$11.1M | -$16.0M | -$15.5M | -$22.3M | -$18.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.